Doctor Jeanmarie Guenot’s Current Exploits: Consequences of Past Impeccable Attainments

JeanMarie Guenot has been replicating the qualities everybody knows about her since joining Amphivena Therapeutics as CEO and President. It came as no surprise because she has a solid foundation. Guenot together with her team in Amphivena is helping to curb the spread of cancer, and hopefully, eradicate it altogether in the nearest future.

Statistics about cancer cases is not encouraging with 19 million people expected to be diagnosed with it by the year 2024. Amphivena Therapeutics under the leadership of JeanMarie Guenot is leaving no stone unturned by joining forces with multiple alliances so as to bring together massive resources and know-how in the fight against this horrible disease.

On the 10th of August, 2016, it was in the news that the U.S. Food and Drug Administration (FDA) approved an investigational new drug application for AMV564, the Amphivena Therapeutics’ proprietary antibody. AMV564 is a bispecific antibody that makes use of T-cells in getting rid of cancer cells with CD33. CD33 is a particular receptor commonly found in most cases of AMLs, which is also expressed on other hematological malignancies.

Also, on the 7th of April, 2015, according to guenotllc.com, Amphivena Therapeutics, Inc. made public some milestones achievement under the terms of agreement between Janssen Biotech, Inc and itself. Janssen and Amphivena, in furtherance of development in hematologic malignancies, selected a clinical candidate against an unnamed tumor antigen. The milestones came with financial benefits for Amphivena.

Guenot’s wealth of experience in the pharmaceutical and biotechnology industry started with Atlas Venture while she was managing its venture capital investments. She also spent time working as a scientist with the Preclinical Research and Development arm of Hoffman LaRoache. Hoffman LaRoache is a company that focuses on dry AMD together with sustained release ocular drug delivery technologies for macular degeneration, ocular inflammation and glaucoma. Today, she is in a firm that develops cancer immunotherapies.

JeanMarie Guenot holds a PhD and MBA from the University of California, San Francisco and the Wharton School at the University of Pennsylvania.

Read more: Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies

Leave a Reply

Your email address will not be published. Required fields are marked *